Protalix (PLX): Customer Map and Commercial Implications
Protalix Biotherapeutics is a small-cap biopharma that monetizes by manufacturing and selling recombinant proteins through partner commercialization agreements and direct government sales. The company produces proprietary biologics via its ProCellEx plant cell expression platform, then either ships finished product to institutional customers or supplies drug substance under long-term supply contracts and licensing arrangements; revenue flows come from product sales, milestone payments and partner royalties. For investors, the critical takeaway is that Protalix’s near-term revenue profile is partner-driven and concentrated: a few large customers and commercialization partners account for a meaningful share of reported sales.
Learn more and explore commercial counterparties at https://nullexposure.com/.
How Protalix makes money and why customers matter
Protalix’s cash generation rests on two commercial pillars: (1) partnered commercialization (Chiesi for PRX‑102 / Elfabrio; Pfizer for taliglucerase alfa / Elelyso outside Brazil) and (2) direct supply agreements to public health organizations (notably Brazil’s Fiocruz / Fundação Oswaldo Cruz). The company recognizes revenue at delivery and records multi‑million dollar annual sales lines to these counterparties; regulatory milestones such as the European Commission’s dosing approval for Elfabrio also create discrete upside events. These relationships convert Protalix’s manufacturing capacity into predictable revenue streams but also concentrate counterparty risk.
Operating constraints that shape the customer model
- Long-term contracts exist with major partners. The company disclosed multi‑year supply commitments—specifically noting an amended Pfizer agreement and multi‑year terms—indicating that at least some customer flows are contractually durable (Form 10‑K, FY2024).
- Protalix is both a manufacturer and a seller. The 10‑K explicitly states Protalix (and Protalix Ltd.) as the sole manufacturer of specific products sold to partners, while the company also recognizes point‑of‑sale product revenues upon delivery; this dual role makes PLX a critical upstream supplier for partner commercialization programs.
- Revenue concentration and spend band. Reported sales lines in FY2024 place major customers in the $10m–$100m annual spend band (e.g., Elfabrio and Elelyso flows), so individual counterparties are material to near‑term revenue.
- Counterparty credit posture is lightweight. Protalix does not require receivables collateral from customers, which implies exposed trade receivables and greater sensitivity to counterparty payment behavior (company filing commentary).
- Active commercial stage. Since regulatory approvals in 2023, Protalix has been recognizing manufacturing revenue tied to partner launches and public‑health supply agreements (management commentary and Form 10‑K).
If you want a consolidated customer-risk score or a quick visual of who pays PLX, visit https://nullexposure.com/ for a closer view.
Customer relationships — line by line (each relationship in the record)
Below are plain‑English one‑to‑two sentence synopses for every customer name captured in the company’s filings and press coverage.
Chiesi
Protalix reported that sales to Chiesi were a substantial driver of revenue growth in FY2024, with an $11.8 million increase year‑over‑year noted in the FY2024 Form 10‑K (plx‑2024‑12‑31). According to the company’s disclosure, Chiesi is a primary commercialization partner for pegunigalsidase alfa (Elfabrio).
Chiesi (Italy)
The FY2024 Form 10‑K breaks out Fabry‑disease sales to Chiesi (Italy), listing an FY2024 figure in the reported sales table (plx‑2024‑12‑31), which reflects the Italy unit’s material contribution to Elfabrio revenue.
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is the named commercialization unit partnered with Protalix for PRX‑102/Elfabrio; press coverage around the European approval for an additional dosing regimen also highlights that this unit executes global commercial strategy and triggers milestone payments to Protalix (Proactive Investors and GlobeNewswire, FY2026).
Chiesi Farmaceutici S.p.A.
Protalix has repeatedly described a global development and commercialization partnership with Chiesi Farmaceutici S.p.A. for pegunigalsidase alfa; the company submitted regulatory filings and coordinated Phase III programs with this partner (PR Newswire releases, FY2021–FY2023).
Chiesi Rare Disease
Analyst and research commentary described “Chiesi Rare Disease” as the commercial organization expected to commercialize Elfabrio globally, underscoring Chiesi’s role in product roll‑out (Research‑Tree / Zacks commentary, FY2026).
Pfizer
Management confirmed on the FY2025 Q3 earnings call that Protalix recognizes revenues from product sales to Pfizer, reflecting ongoing commercial and supply activity tied to Protalix’s Gaucher disease product (plx‑2025q3‑earnings‑call).
Pfizer Inc.
Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa to Pfizer Inc., with Protalix retaining Brazil rights, a licensing arrangement disclosed in company releases and investor letters (PR Newswire company letter, FY2023).
Pfizer (Ireland)
The FY2024 Form 10‑K shows a dedicated sales line for Gaucher disease to “Pfizer (Ireland)” with multi‑year amounts reported, indicating an entity‑level channel used for Elelyso commercialization outside Brazil (plx‑2024‑12‑31).
Pfizer Inc.
(duplicate naming in press feeds) Multiple press releases and news items from FY2021–FY2026 reiterate that Pfizer holds commercialization rights for Elelyso in markets outside Brazil and is a recurring revenue source for Protalix (company press releases and news aggregators, FY2021–FY2026).
Fiocruz
Earnings call commentary confirms Protalix recognizes revenue from sales to Fiocruz in Brazil, reflecting the company’s supply and technology‑transfer arrangements with Brazil’s public health institution (plx‑2025q3‑earnings‑call).
Fiocruz (Brazil)
The FY2024 Form 10‑K lists line‑item sales to “Fiocruz (Brazil)” with escalating annual amounts, demonstrating that Fiocruz is a multi‑million dollar purchaser and an active commercial customer (plx‑2024‑12‑31).
Fundação Oswaldo Cruz
Public commentary and investor presentations reference ongoing contributions from Elelyso through collaborations with Fundação Oswaldo Cruz, emphasizing a formal institutional buyer role in Brazil’s market (Proactive Investors, FY2026).
Funda o Oswaldo Cruz
The FY2024 Form 10‑K specifically warns about risks tied to compliance by “Funda o Oswaldo Cruz” (Fiocruz) with its purchase obligations under a supply and technology transfer agreement, signaling contractual performance risk on a material government counterparty (plx‑2024‑12‑31).
SarcoMed USA
Protalix entered an exclusive worldwide license agreement with SarcoMed USA to advance PRX‑110 (alidornase alfa) for pulmonary sarcoidosis and related respiratory diseases, representing a pipeline‑stage partnering relationship (SarcoidosisNews coverage, FY2021).
If you want an investor‑grade matrix showing revenue lines, contract terms and milestone timing for each of these counterparties, see https://nullexposure.com/.
Investment implications — synthesis and risk points
- Concentration risk is material. Multiple FY2024 lines and management commentary show that a handful of partners (Chiesi, Pfizer, Fiocruz) account for most product sales; a single adverse event or a missed payment would have outsized P&L impact.
- Contracted manufacturing is a lender‑friendly attribute but creates dependency. Protalix’s role as the sole manufacturer for certain products creates durable revenue opportunities but also concentrates execution risk in its production footprint. The 10‑K documents long supply terms with major partners.
- Milestones lift optionality. The European Commission approval that triggered a $25 million regulatory milestone from Chiesi is an example of non‑linear upside that is separate from recurring sales (news releases, FY2026).
- Public‑sector counterparty risk is explicit. Filings call out potential compliance risk for Brazil’s Fiocruz under supply agreements, a credit and timing risk for large government receivables.
What to watch next
- Trajectory of Elfabrio uptake under Chiesi’s commercial plan and timing of associated milestone receipts.
- Execution under the Pfizer supply arrangement and any renewals/extensions of that multi‑year contract disclosed in filings.
- Cash collection and receivable aging tied to Fiocruz / Fundação Oswaldo Cruz given the corporate disclosure of compliance risk.
For a focused review of PLX counterparties, contract durations and revenue exposure, run a tailored customer risk report at https://nullexposure.com/ — the single destination for counterparty intelligence and commercial concentration analysis.
Disclaimer: This is commentary for investment research purposes based on Protalix public filings and market reporting; review primary filings for contractual detail.